OAM
NMRA icon

Oxford Asset Management’s Neumora Therapeutics NMRA Stock Holding History

Oxford Asset Management’s Portfolio NMRA Stock Details NMRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-10,000
Closed -$138K – 383
2024
Q1 		$138K Buy
+10,000
New +$162K 0.14% 212

Other funds holding NMRA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return
IC
Iconiq Capital San Francisco, California $4.46B AUM 22.86% 1-Year Est. Return
WT
Wellcome Trust London, United Kingdom $9.01B AUM 12.05% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Oxford Asset Management's NMRA Position: Q2 2024 in Review

Oxford Asset Management sold out of Neumora Therapeutics (NMRA) in Q2 2024, closing a stake of 10,000 shares — an estimated $138K sold.

Oxford Asset Management first reported a position in NMRA in Q1 2024 and held it in 1 quarter. The position peaked at $138K in Q1 2024. 93 funds tracked by Wall St. Rank hold NMRA as of Q2 2024.

  • Oxford Asset Management reported no remaining Neumora Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Oxford Asset Management sold 10,000 Neumora Therapeutics shares in Q2 2024, an estimated $138K.
  • Oxford Asset Management first reported a position in Neumora Therapeutics in Q1 2024 and held it in 1 quarter.
  • Oxford Asset Management's Neumora Therapeutics position peaked at $138K in Q1 2024.
  • 93 funds tracked by Wall St. Rank held Neumora Therapeutics as of Q2 2024.

Based on Oxford Asset Management's 13F filing for Q2 2024, filed 14 Aug 2024.